ReviewCurrent opinion in immunology2013
Materials based tumor immunotherapy vaccines.
Review in Current opinion in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Biochemical hallmarks-targeting antineoplastic nanotherapeutics.Bioactive materials · 2024Review
- Article
- Oxygen-Generating Cryogels Restore T Cell Mediated Cytotoxicity in Hypoxic Tumors.Advanced functional materials · 2021Article
- Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy.International journal of molecular sciences · 2021Review
- Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Rational vaccinology with spherical nucleic acids.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Enhanced anti-tumor immunotherapy by silica-coated magnetic nanoparticles conjugated with ovalbumin.International journal of nanomedicine · 2019Article
- A facile approach for development of a vaccine made of bacterial double-layered membrane vesicles (DMVs).Biomaterials · 2018Article
- Injectable, Tough Alginate Cryogels as Cancer Vaccines.Advanced healthcare materials · 2018Article
- Improved magnetic regulation of delivery profiles from ferrogels.Biomaterials · 2018Article
- Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment.Chemical reviews · 2017Review
- Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface.Molecular pharmaceutics · 2017Article
- The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration.Biomaterials · 2016Article
- Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.Nature reviews. Cancer · 2016Review
- Engineering opportunities in cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2015Review
- Injectable cryogel-based whole-cell cancer vaccines.Nature communications · 2015Article
- Boon and Bane of Inflammation in Bone Tissue Regeneration and Its Link with Angiogenesis.Tissue engineering. Part B, Reviews · 2015Review
- Manipulating the intersection of angiogenesis and inflammation.Annals of biomedical engineering · 2015Review
- Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering.Journal of cellular biochemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy is a promising approach for treating cancer. However, there are limitations inherent to current approaches which may be addressed by integrating them with biomaterial-based strategies. Material platforms have been fabricated to interact with immune cells through spatially controlled and temporally controlled delivery of immune modulators and to promote immune cell crosstalk. Particle vaccines have been developed to specifically target and deliver agents to organs, cells and subcellular compartments. These strategies have been shown to generate antigen-specific CTL responses and, in some cases, tumor regression. Therefore, collaboration between immunology and materials engineering is likely to result in the creation of strong vaccines to combat cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.